Novo Nordisk A/S experienced a significant downturn after trimming its 2025 financial outlook, marking the second revision this year due to growing headwinds in key markets. Sales growth is now projected to be 8-14% with operating profit growth at 10-16%, down from earlier forecasts due to slower-than-expected growth in GLP-1 treatments in the U.S. and increased competition. Novo Nordisk has launched initiatives to combat knockoff drugs and anticipates regulatory decisions for new indications. The company also announced a leadership change, with Maziar Mike Doustdar appointed as the new CEO. Stock prices dropped 18.5% in premarket trading.

Read more at Yahoo Finance: Ozempic And Wegovy Maker Cuts Outlook In Surprise Move, Picks New CEO